Abstract:Pancreatic ductal adenocarcinoma (PDAC) is a highly aggressive and malignant neoplasm. The aberrant expression of miR-135b-5p and secreted frizzled-related protein 4 (SFRP4) has been revealed to be involved in various cancers. However, the clinical significance of miR-135b-5p and that of its potential target SFRP4 in PDAC remain to be elucidated. Here, we found that miR-135b-5p was markedly upregulated in pancreatic cancer tissue compared with corresponding adjacent normal tissue, whereas SFRP4 was significantly downregulated. The expression of miR-135b-5p was negatively correlated with the expression of SFRP4. PDAC patients with regional lymph node metastases, vascular invasion, tumor microthrombus and higher PET-CT SUVmax values had significantly higher expression of miR-135b-5p. Immunoblotting revealed that regional lymph node metastases were correlated with expressive states of SFRP4. Negative SFRP4 expression was significantly associated with old age, larger tumor size, regional lymph node metastasis and poor differentiation. Survival analyses demonstrated that miR-135b-5p and SFRP4 could predict outcomes and that miR-135b-5p was an independent predictor. In vitro, the overexpression of miR-135b-5p promoted the migration and proliferation of PANC-1 and MiaPaCa-2 cells, while immunoblotting demonstrated the downregulation of SFRP4 and the upregulation of beta-catenin. Inhibition of miR-135b-5p suppressed migration, induced apoptosis of PANC-1 and AsPC-1 cells, and reduced the expression of beta-catenin. A luciferase reporter assay confirmed that miR-135b-5p repressed the expression of SFRP4 via the direct targeting of its 3'-untranslated regions. In conclusion, the overexpression of miR-135b-5p and the downregulation of SFRP4 were associated with unfavorable clinical characteristics and poor prognosis, and SFRP4 was shown to be a direct downstream target of miR-135b-5p. Thus, the mechanism that underlies the miR-135b-5p-SFRP4-Wnt/beta-catenin axis represents a potential target for PDAC diagnosis and therapy.

SF3B4 is decreased in pancreatic cancer and inhibits the growth and migration of cancer cells.

MiR-337 Suppresses Pancreatic Cancer Development Via STAT3/Wnt/β-catenin Axis.

MicroRNA-204-3p Inhibits Metastasis of Pancreatic Cancer Via Downregulating MGAT1.

Long Non-Coding RNA DSCAM-AS1 Promotes Pancreatic Cancer Progression Via Regulating the Mir-136-5p/pbx3 Axis

SF3B4 is Regulated by Microrna-133B and Promotes Cell Proliferation and Metastasis in Hepatocellular Carcinoma

S100A4 promotes pancreatic cancer progression through a dual signaling pathway mediated by Src and focal adhesion kinase

The Splicing Factor SF3B4 Drives Proliferation and Invasion in Cervical Cancer by Regulating SPAG5

SF3B4 Regulates Cellular Senescence and Suppresses Therapy-induced Senescence of Cancer Cells

EIF3B promotes cancer progression in pancreatic cancer

Overexpression of Mir-135b-5p Promotes Unfavorable Clinical Characteristics and Poor Prognosis Via the Repression of Sfrp4 in Pancreatic Cancer

Decreased Tusc3 Promotes Pancreatic Cancer Proliferation, Invasion And Metastasis

MicroRNA-34b inhibits pancreatic cancer metastasis through repressing Smad3.

SF3B1 mutation in pancreatic cancer contributes to aerobic glycolysis and tumor growth through a PP2A-c-Myc axis

SF3B4 promotes ovarian cancer progression by regulating alternative splicing of RAD52

SF3B4 downregulation restrains lung adenocarcinoma tumorigenesis via 5′ alternative splicing of KAT2A

Trefoil Factor 3 Promotes Pancreatic Carcinoma Progression Via WNT Pathway Activation Mediated by Enhanced WNT Ligand Expression

KLF4α Up-regulation Promotes Cell Cycle Progression and Reduces Survival Time of Patients with Pancreatic Cancer

Exploring Splicing Modulation as an Innovative Approach to Combat Pancreatic Cancer: SF3B1 Emerges as a Prognostic Indicator and Therapeutic Target

MicroRNA-301a-3p Promotes Pancreatic Cancer Progression Via Negative Regulation Ofsmad4

SRSF1 Prevents DNA Damage and Promotes Tumorigenesis Through Regulation of DBF4B Pre-mRNA Splicing.

P300 reduces TUBB4B expression to facilitate the biological process of migration and invasion of non-small cell lung cancer cells